RxDoctor Payments Data

Bhupinder Sangha, MD

Critical Care Medicine · Seguin, TXNPI 1457594863

Payments from drug & device makers

$2,130in general payments, 2019–2025

Across 44 payments — averaging $48.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • GSK$129
  • Actelion Pharmaceuticals US, Inc.$127
  • Boston Scientific$118
  • Tactile Systems Technology Inc$89
  • Inari Medical, Inc.$85
  • plus $291 from 12 others

What the payments were for

  • Travel & lodging$1,06150%
  • Food & beverage$97146%
  • Education$995%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,130 in reported general payments places this provider in the 70th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$141,511
Medicare patients
755
Services billed
2,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan16$194,958
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$28,536
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$28,175
FarxigaDapagliflozin Propanediol16$10,400
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$4,440
Sevelamer Carbonate20$2,194
Clonidine20$1,934
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,336
Albuterol Sulfate HfaAlbuterol Sulfate37$951
Bumetanide21$841
Losartan Potassium52$300
Nifedipine ErNifedipine16$264
Lisinopril12$262
Carvedilol36$252
Pravastatin Sodium16$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$127$194,95816 claims
AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere$20$43,01566 claims
GSKTrelegy Ellipta$129$28,53640 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →